Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

Cited In for PubMed (Select 20427152)

1.

Drug resistance analysis by next generation sequencing in Leishmania.

Leprohon P, Fernandez-Prada C, Gazanion É, Monte-Neto R, Ouellette M.

Int J Parasitol Drugs Drug Resist. 2014 Sep 22;5(1):26-35. doi: 10.1016/j.ijpddr.2014.09.005. eCollection 2015 Apr. Review.

2.

Heterogeneity of molecular resistance patterns in antimony-resistant field isolates of Leishmania species from the western Mediterranean area.

Jeddi F, Mary C, Aoun K, Harrat Z, Bouratbine A, Faraut F, Benikhlef R, Pomares C, Pratlong F, Marty P, Piarroux R.

Antimicrob Agents Chemother. 2014 Aug;58(8):4866-74. doi: 10.1128/AAC.02521-13. Epub 2014 Jun 9.

3.

Characterization of the proliferating cell nuclear antigen of Leishmania donovani clinical isolates and its association with antimony resistance.

Tandon R, Chandra S, Baharia RK, Das S, Misra P, Kumar A, Siddiqi MI, Sundar S, Dube A.

Antimicrob Agents Chemother. 2014 Jun;58(6):2997-3007. doi: 10.1128/AAC.01847-13. Epub 2014 Mar 10.

4.

Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani.

Bhandari V, Sundar S, Dujardin JC, Salotra P.

Antimicrob Agents Chemother. 2014 May;58(5):2580-5. doi: 10.1128/AAC.01574-13. Epub 2014 Feb 18.

5.

Antimony resistance and environment: Elusive links to explore during Leishmania life cycle.

Sereno D, Maia C, Aït-Oudhia K.

Int J Parasitol Drugs Drug Resist. 2012 Sep 3;2:200-3. doi: 10.1016/j.ijpddr.2012.07.003. eCollection 2012 Dec.

6.

Proteomic and genomic analyses of antimony resistant Leishmania infantum mutant.

Brotherton MC, Bourassa S, Leprohon P, Légaré D, Poirier GG, Droit A, Ouellette M.

PLoS One. 2013 Nov 27;8(11):e81899. doi: 10.1371/journal.pone.0081899. eCollection 2013.

7.

Drug resistance in natural isolates of Leishmania donovani s.l. promastigotes is dependent of Pgp170 expression.

Messaritakis I, Christodoulou V, Mazeris A, Koutala E, Vlahou A, Papadogiorgaki S, Antoniou M.

PLoS One. 2013 Jun 11;8(6):e65467. doi: 10.1371/journal.pone.0065467. Print 2013.

8.

Molecular mechanisms of drug resistance in natural Leishmania populations vary with genetic background.

Decuypere S, Vanaerschot M, Brunker K, Imamura H, Müller S, Khanal B, Rijal S, Dujardin JC, Coombs GH.

PLoS Negl Trop Dis. 2012;6(2):e1514. doi: 10.1371/journal.pntd.0001514. Epub 2012 Feb 28.

9.

Antimony resistance in leishmania, focusing on experimental research.

Jeddi F, Piarroux R, Mary C.

J Trop Med. 2011;2011:695382. doi: 10.1155/2011/695382. Epub 2011 Nov 17.

10.

Downregulation of mitogen-activated protein kinase 1 of Leishmania donovani field isolates is associated with antimony resistance.

Ashutosh, Garg M, Sundar S, Duncan R, Nakhasi HL, Goyal N.

Antimicrob Agents Chemother. 2012 Jan;56(1):518-25. doi: 10.1128/AAC.00736-11. Epub 2011 Nov 7.

11.

Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance.

Downing T, Imamura H, Decuypere S, Clark TG, Coombs GH, Cotton JA, Hilley JD, de Doncker S, Maes I, Mottram JC, Quail MA, Rijal S, Sanders M, Schönian G, Stark O, Sundar S, Vanaerschot M, Hertz-Fowler C, Dujardin JC, Berriman M.

Genome Res. 2011 Dec;21(12):2143-56. doi: 10.1101/gr.123430.111. Epub 2011 Oct 28.

12.

Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine.

Kulshrestha A, Singh R, Kumar D, Negi NS, Salotra P.

Antimicrob Agents Chemother. 2011 Jun;55(6):2916-21. doi: 10.1128/AAC.00812-10. Epub 2011 Apr 4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk